Accelerate Oncology Drug Discovery with Rapid Drug Efficacy Testing

The increasing complexity of oncology drug development requires preclinical models that deliver clinically relevant, predictive, and reproducible results. Traditional 2D and 3D cell approaches often suffer from differentiation, variability in organoid size, morphology, growth conditions, cellular communication, and assay read-outs. These inconsistencies can lead to significant experimental variability and make the comparison of results between studies difficult. 

abc biopply AG, Europe's first fully integrated Organoid CRO, provides validated preclinical services based on its proprietary 3D CoSeedis™ Humanized Multi-Organoid Technology, enabling more reliable efficacy, safety, toxicity, resistance, and biomarker studies in drug discovery and development. Instead of cultivating a limited number of isolated organoids in standard plastic ware, the CoSeedis™ platform enables the formation of highly standardized micro-tissues consisting of hundreds of communicating organoids under controlled and validated conditions. This results in superior reproducibility, scalability, and translational relevance for drug discovery programs. 

Why Standardized Multi-Organoid Models Deliver Better Results 
✅ Physiologically Relevant Models 
CoSeedis™ micro-tissues closely mimic the in vivo architecture and tumor microenvironment, delivering more realistic drug response data. 
✅ Enhanced Predictivity 
Each CoSeedis™ chip contains 500 to 1,000 interacting organoids, improving the prediction of efficacy and toxicity compared to traditional models. 
✅ Humanized Disease Models 
Continuous communication between patient-derived cancer (PDC) organoids better reflects human genetic diversity, supporting more personalized drug development strategies. 
✅ Rapid Decision-Making 
Early identification of promising candidates reduces development risks, shortens timelines, and lowers overall R&D costs. 
 
 
How can you profit: Rapid Drug Efficacy Check Package 
(One Drug – One Target) 
Designed for hit validation, lead optimization, and preclinical candidate selection, you profit from a package which delivers rapid and highly predictive efficacy results and IND data: 

1. Selection of a suitable 3D CoSeedis™ tumor model
2. 2D Cytotoxicity Assay for initial toxicity validation
3. Design and validation of a customized 3D disease model
4. 3D CoSeedis™ Cytotoxicity In-Chip Assay integrating over 680 data points for highly accurate IC50 determination
5. 3D CoSeedis™ Dose Response Assay to evaluate drug effects over time and support dose optimization 

Key Deliverables

• Disease model design and validation
• 2D versus 3D comparative analysis
• Physiological target cytotoxicity (IC50)
• Ex vivo dose-response profiling
• Predictive performance benchmarking
• Detailed customer-specific final report 
   

Fully Integrated Preclinical CRO Services 
Beyond rapid drug efficacy testing, abc biopply offers a comprehensive portfolio of validated preclinical services based on clinically relevant disease models across oncology, neurology, hepatic, renal, obesity, cartilage, and other indications. 

Our service portfolio includes: 

• Drug efficacy studies
• Drug safety and toxicity testing
• On-target and off-target toxicity assessments
• Drug resistance studies
• Tumor relapse investigations
• Biomarker and marker studies
• Tissue penetration studies
• Omics-based analyses
• Custom-tailored model development
• Integrated study design and planning

For advanced translational projects, in vitro organoid studies can be synchronized with humanized in vivo mouse models through our partner network, creating a seamless preclinical development workflow. 
 
Organoid Competence Center 
To ensure robust, standardized, and IND-relevant outcomes, abc biopply operates dedicated Organoid Competence Centers, including its recently established facility at the Swiss Innovation Park Basel Area, one of Europe's leading drug discovery hubs.  

These centers provide: 

• Standardized organoid model development
• Validated assay execution
• High-quality translational data generation
• Direct collaboration with pharmaceutical and biotechnology partners
• Scalable implementation and technology licensing opportunities 

By combining scientific expertise, standardized workflows, and proprietary 3D CoSeedis™ technology, our Organoid Competence Centers help customers generate reproducible data that supports better go/no-go decisions earlier in development. 

Let's Discuss Your Next Study 
Whether you are evaluating novel oncology compounds, investigating resistance mechanisms, validating biomarkers, or developing customized disease models, abc biopply can support your project with highly predictive and translationally relevant organoid-based preclinical services. 

We would welcome the opportunity to discuss how our Rapid Drug Efficacy Check Package and integrated preclinicalCRO services can accelerate your oncology pipeline.